Search results
Age-Related Macular Degeneration: Putting a Hole in Our World
WebMD· 6 hours agoWhen we’re young, we take our macula for granted. At the center of our retina – the deepest layer of the eye that’s chock-full of photoreceptors and that confers color to our world – the macula ...
Earnings call: Lineage Cell Therapeutics reports positive OpRegen trial results By Investing.com
Investing.com· 2 hours agoIn a recent earnings call, Lineage Cell Therapeutics (NYSE:LCTX), a biotechnology company...
The American Macular Degeneration Foundation Showc | Newswise
Newswise· 2 days ago“Our goal is to advance the development of treatments, tools and usable information that improve the lives of those affected by AMD and, just as important, a sense of hope ...
Lineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue Declines
GuruFocus.com via Yahoo Finance· 2 hours agoThe company also reported positive long-term data from its OpRegen treatment, showing sustained visual benefits, which underscores the therapys potential in treating geographic ...
Kyowa Kirin Will Present Pre-Clinical Data at the Association for Research in Vision and...
Char-Koosta News· 2 days agoAge-related macular degeneration (AMD) is a leading cause of severe vision loss for people aged 50 years and older in developed countries worldwide, with ...
EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges
GuruFocus.com via Yahoo Finance· 3 hours agoThe company utilizes its proprietary Durasert E and Verisome technology platforms to develop ...
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
GuruFocus.com via Yahoo Finance· 2 hours agoIts flagship product, ADVM-022 (Ixo-vec), aims to revolutionize care for patients with wet age-related macular degeneration (AMD) by reducing the frequency ...
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says Oppenheimer
TipRanks via Yahoo Finance· 1 day agoRisk and reward are the yin and yang of stock trading, the two essential yet opposing forces in...
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Market Watch· 4 days agodropped nearly 30% in premarket trading Monday after the company said its experimental...
EyePoint reports mixed results in diabetic retinopathy trial By Investing.com
Investing.com· 4 days agoEyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) announced interim results from its Phase 2...